Positron Emission Tomography for Benign and Malignant Disease

Surgical Clinics of North America

Volumn 91, Issue 1, 2011, Pages 249-266

  Visioni, Anthony ^a   Kim, Julian ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Fluorodeoxyglucose; Imaging; Positron emission tomography

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18;

AXILLARY LYMPH NODE; BONE TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; EPILEPSY; ESOPHAGUS CANCER; FALSE NEGATIVE RESULT; FEVER; GERM CELL TUMOR; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; LABORATORY TEST; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOMA; MAMMOGRAPHY; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MEDICAL CARE; MELANOMA; MOTOR DYSFUNCTION; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PEDIATRICS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SOFT TISSUE TUMOR; STROKE; TREATMENT PLANNING; ULTRASOUND; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DERMATITIS, CONTACT; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SOLITARY PULMONARY NODULE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650278278     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.10.012     Document Type: Review

References (94)

1. Antonini A., DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med 2004, 5(2):201-206.
2. Ceballos-Baumann A.O. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol 2003, 250(Suppl 1):I15-I23.
3. Fukuyama H. Functional brain imaging in Parkinson's disease-overview. J Neurol 2004, 251(Suppl 7):vII1-vII3.
4. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
5. Higgins G.A., Shields T.W., Keehn R.J. The solitary pulmonary nodule. Ten-year follow-up of Veterans Administration-Armed Forces Cooperative Study. Arch Surg 1975, 110(5):570-575.
6. Cronin P., Dwamena B.A., Kelly A.M., et al. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008, 246(3):772-782.
7. Bar-Shalom R., Kagna O., Israel O., et al. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-d-glucose avidity on positron emission tomography/computed tomography. Cancer 2008, 113(11):3213-3221.
8. Kim S.K., Allen-Auerbach M., Goldin J., et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007, 48(2):214-220.
9. Yi C.A., Lee K.S., Kim B.T., et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006, 47(3):443-450.
10. Chang C.Y., Tzao C., Lee S.C., et al. Incremental value of integrated FDG-PET/CT in evaluating indeterminate solitary pulmonary nodule for malignancy. Mol Imaging Biol 2010, 12(2):204-209.
11. Shim S.S., Lee K.S., Kim B.-T., et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005, 236:1011.
12. Liu B.J., Dong J.C., Xu C.Q., et al. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers. Chin Med J (Engl) 2009, 122(15):1749-1754.
13. Tasci E., Tezel C., Orki A., et al. The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2009, 10(2):200-203.
14. Carnochan F.M., Walker W.S. Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg 2009, 35(5):781-785.
15. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361(1):32-39.
16. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004, 45(10):1640-1646.
17. Bogot N.R., Quint L.E. Imaging of recurrent lung cancer. Cancer Imaging 2004, 4(2):61-67.
18. Collins C.D. PET/CT in oncology: for which tumours is it the reference standard?. Cancer Imaging 2007, 7(Special Issue A):S77-S87.
19. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000, 18(20):3495-3502.
20. Heusner T.A., Kuemmel S., Umutlu L., et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008, 49(8):1215-1222.
21. Bowen S.L., Wu Y., Chaudhari A.J., et al. Initial characterization of a dedicated breast PET/CT scanner during human imaging. J Nucl Med 2009, 50(9):1401-1408.
22. Murthy K., Aznar M., Thompson C.J., et al. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000, 41(11):1851-1858.
23. Levine E.A., Freimanis R.I., Perrier N.D., et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 2003, 10(1):86-91.
24. Yang S.K., Cho N., Moon W.K. The role of PET/CT for evaluating breast cancer. Korean J Radiol 2007, 8(5):429-437.
25. Rosen E.L., Turkington T.G., Soo M.S., et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005, 234(2):527-534.
26. Taira N., Ohsumi S., Takabatake D., et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol 2009, 39(1):16-21.
27. Chae B.J., Bae J.S., Kang B.J., et al. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer. Jpn J Clin Oncol 2009, 39(5):284-289.
28. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-d-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001, 93(8):630-635.
29. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001, 28(3):351-358.
30. Kim J., Lee J., Chang E., et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009, 33(5):943-949.
31. Radan L., Ben-Haim S., Bar-Shalom R., et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006, 107(11):2545-2551.
32. Veit-Haibach P., Antoch G., Beyer T., et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007, 80(955):508-515.
33. Pan L., Han Y., Sun X., et al. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol 2010, 136(7):1007-1022.
34. Cookson M.S., Fleshner N.E., Soloway S.M., et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997, 157(2):559-562.
35. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998, 39(6):990-995.
36. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000, 27(9):1415-1419.
37. Farsad M., Schiavina R., Castellucci P., et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005, 46(10):1642-1649.
38. Piert M., Park H., Khan A., et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009, 50(10):1585-1593.
39. Danella J.F., deKernion J.B., Smith R.B., et al. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993, 149(6):1488-1491.
40. de Jong I.J., Pruim J., Elsinga P.H., et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003, 44(3):331-335.
41. Bromer M.Q., Weinberg D.S. Screening for colorectal cancer-now and the near future. Semin Oncol 2005, 32(1):3-10.
42. Mulhall B.P., Veerappan G.R., Jackson J.L. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005, 142(8):635-650.
43. Gollub M.J., Akhurst T., Markowitz A.J., et al. Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. AJR Am J Roentgenol 2007, 188(1):130-138.
44. Taylor S.A., Bomanji J.B., Manpanzure L., et al. Nonlaxative PET/CT colonography: feasibility, acceptability, and pilot performance in patients at higher risk of colonic neoplasia. J Nucl Med 2010, 51(6):854-861.
45. Mainenti P.P., Salvatore B., D'Antonio D., et al. PET/CT colonography in patients with colorectal polyps: a feasibility study. Eur J Nucl Med Mol Imaging 2007, 34(10):1594-1603.
46. Veit P., Kuhle C., Beyer T., et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006, 55(1):68-73.
47. Kinner S., Antoch G., Bockisch A., et al. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007, 32(5):606-612.
48. Bennett J.J., Cao D., Posner M.C. Determinants of unresectability and outcome of patients with occult colorectal hepatic metastases. J Surg Oncol 2005, 92(1):64-69.
49. Sørensen M., Mortensen F.V., Høyer M., et al. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg 2007, 96:209-213.
50. Ruers T.J., Langenhoff B.S., Neeleman N., et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002, 20(2):388-395.
51. Park I.J., Kim H.C., Yu C.S., et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006, 32(9):941-947.
52. Vriens D., de Geus-Oei L.F., van der Graaf W.T., et al. Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging 2009, 53(2):224-244.
53. von Schulthess G.K., Steinert H.C., Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 2006, 238(2):405-422.
54. Votrubova J., Belohlavek O., Jaruskova M., et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006, 33(7):779-784.
55. Chen L.-B., Tong J.-L., Hai-Zhu S., et al. 18F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007, 13(37):5025-5029.
56. Soyka J.D., Veit-Haibach P., Strobel K., et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med 2008, 49(3):354-361.
57. Vogel W.V., Wiering B., Corstens F.H., et al. Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging 2005, 5(Spec No A):S143-S149.
58. Yancovitz M., Finelt N., Warycha M.A., et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007, 110(5):1107-1114.
59. Havenga K., Cobben D.C., Oyen W.J., et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003, 29(8):662-664.
60. Crippa F., Leutner M., Belli F., et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000, 41(9):1491-1494.
61. Acland K.M., Healy C., Calonje E., et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001, 19(10):2674-2678.
62. Strobel K., Dummer R., Husarik D.B., et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007, 244(2):566-574.
63. Tyler D.S., Onaitis M., Kherani A., et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000, 89(5):1019-1025.
64. Branstetter B.F., Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone?. Radiology 2005, 235(2):580-586.
65. Hannah A., Scott A.M., Tochon-Danguy H., et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002, 236(2):208-217.
66. Bailet J.W., Abemayor E., Jabour B.A., et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992, 102(3):281-288.
67. Braams J.W., Pruim J., Freling N.J., et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995, 36(2):211-216.
68. Schoder H., Yeung H.W., Gonen M., et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004, 231(1):65-72.
69. Nahmias C., Carlson E.R., Duncan L.D., et al. Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. J Oral Maxillofac Surg 2007, 65(12):2524-2535.
70. Schoder H., Carlson D.L., Kraus D.H., et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006, 47(5):755-762.
71. Kim S.Y., Roh J.L., Yeo N.K., et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007, 18(10):1698-1703.
72. Quon A., Fischbein N.J., McDougall I.R., et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007, 48(Suppl 1):58S-67S.
73. Abgral R., Querellou S., Potard G., et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?. J Nucl Med 2009, 50(1):24-29.
74. Bortfeld T. IMRT: a review and preview. Phys Med Biol 2006, 51(13):R363-R379.
75. Gregoire V., Haustermans K., Geets X., et al. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med 2007, 48(Suppl 1):68S-77S.
76. Gupta T., Beriwal S. PET/CT-guided radiation therapy planning: from present to the future. Indian J Cancer 2010, 47(2):126-133.
77. Krengli M., Milia M.E., Turri L., et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol 2010, 5:10.
78. Jingu K., Ariga H., Kaneta T., et al. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer 2010, 10:127.
79. Topkan E., Yavuz A.A., Aydin M., et al. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 2008, 27:41.
80. Deantonio L., Beldi D., Gambaro G., et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008, 3:29.
81. Coon D., Gokhale A.S., Burton S.A., et al. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer 2008, 9(4):217-221.
82. Ford E.C., Herman J., Yorke E., et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 2009, 50(10):1655-1665.
83. Kruser T.J., Bradley K.A., Bentzen S.M., et al. The impact of hybrid PET-CT scan on overall oncologic management, with a focus on radiotherapy planning: a prospective, blinded study. Technol Cancer Res Treat 2009, 8(2):149-158.
84. Hoffman J.M., Hanson M.W., Friedman H.S., et al. FDG-PET in pediatric posterior fossa brain tumors. J Comput Assist Tomogr 1992, 16(1):62-68.
85. Kumar R., Shandal V., Shamim S.A., et al. Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther 2010, 10(5):755-768.
86. Tatsumi M., Miller J.H., Wahl R.L. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med 2007, 48(12):1923-1931.
87. Murano T., Tateishi U., Iinuma T., et al. Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional X-ray plans in patients with pediatric cancers. Ann Nucl Med 2010, 24(4):261-267.
88. Kleinerman R.A. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006, 36(Suppl 2):121-125.
89. Chawla S.C., Federman N., Zhang D., et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol 2010, 40(5):681-686.
90. Petersdorf R.G. Fever of unknown origin. An old friend revisited. Arch Intern Med 1992, 152(1):21-22.
91. Meller J., Sahlmann C.-O., Scheel A.K. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007, 48:35-45.
92. Halpenny D.F., Burke J.P., Lawlor G.O., et al. Role of PET and combination PET/CT in the evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15(6):951-958.
93. Knaapen P., de Haan S., Hoekstra O.S., et al. Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease. Neth Heart J 2010, 18(2):90-98.
94. Kumar S., Rajshekher G., Prabhakar S. Positron emission tomography in neurological diseases. Neurol India 2005, 53(2):149-155.